{"symbol":"MCOPS12","name":"Microphthalmia, syndromic 12","alternate_names":["MICROPHTHALMIA WITH OR WITHOUT PULMONARY HYPOPLASIA, DIAPHRAGMATIC HERNIA, AND/OR CARDIAC DEFECTS"],"id":"18386","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C3809803","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"615524\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2470\"}","{\"db\":\"OMIM\",\"id\":\"615524\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MICROPHTHALMIA WITH OR WITHOUT PULMONARY HYPOPLASIA, DIAPHRAGMATIC HERNIA, AND/OR CARDIAC DEFECTS\"}","{\"db\":\"OMIM\",\"id\":\"615524\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"XLEPP","name":"Protoporphyria, erythropoietic, X-linked","alternate_names":["ERYTHROHEPATIC PROTOPORPHYRIA, X-LINKED","Erythropoietic Protoporphyria, X-Linked Dominant","X-Linked Protoporphyria"],"id":"4048","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23409301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK121284\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["XLDPP"],"medgen_id":"C2677889","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"300752\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"443197\"}","{\"db\":\"OMIM\",\"id\":\"300752\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROHEPATIC PROTOPORPHYRIA, X-LINKED\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK121284\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"X-Linked Protoporphyria\"}","{\"db\":\"OMIM\",\"id\":\"300752\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XLDPP\"}","{\"db\":\"Genetic Alliance\",\"id\":\"PROTOPORPHYRIA%2C+ERYTHROPOIETIC%2C+X-LINKED/9183\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK121284\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300752\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"X-linked protoporphyria (XLP) is characterized in affected males by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within minutes of sun/light exposure and may be accompanied by swelling and redness. Blistering lesions are uncommon. Pain, which may seem out of proportion to the visible skin lesions, may persist for hours or days after the initial phototoxic reaction. Photosensitivity is lifelong. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. An unknown proportion of individuals with XLP develop liver disease. Except for those with advanced liver disease, life expectancy is not reduced. The phenotype in heterozygous females ranges from asymptomatic to as severe as in affected males.","keywords":[]}
{"symbol":"NEM5","name":"Nemaline myopathy 5","alternate_names":[],"id":"3026","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301465\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1288\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22510848\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["ANM"],"medgen_id":"C1854380","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"605355\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98902\"}","{\"db\":\"OMIM\",\"id\":\"605355\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ANM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8334\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ANM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nemaline+myopathy+5/5127\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8334\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"nemaline-myopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"605355\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8334\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Nemaline myopathy is a disorder that primarily affects skeletal muscles, which are muscles that the body uses for movement. People with nemaline myopathy have muscle weakness (myopathy) throughout the body, but it is typically most severe in the muscles of the face; neck; trunk; and other muscles close to the center of the body (proximal muscles), such as those of the upper arms and legs. This weakness can worsen over time. Affected individuals may have feeding and swallowing difficulties, foot deformities, abnormal curvature of the spine (scoliosis), and joint deformities (contractures). Most people with nemaline myopathy are able to walk, although some affected children may begin walking later than usual. As the condition progresses, some people may require wheelchair assistance. In severe cases, the muscles used for breathing are affected and life-threatening breathing difficulties can occur.Nemaline myopathy is divided into six types. In order of decreasing severity, the types are: severe congenital, Amish, intermediate congenital, typical congenital, childhood-onset, and adult-onset. The types are distinguished by the age when symptoms first appear and the severity of symptoms; however, there is overlap among the various types. The severe congenital type is the most life-threatening. Most individuals with this type do not survive past early childhood due to respiratory failure. The Amish type solely affects the Old Order Amish population of Pennsylvania and is typically fatal in early childhood. The most common type of nemaline myopathy is the typical congenital type, which is characterized by muscle weakness and feeding problems beginning in infancy. Most of these individuals do not have severe breathing problems and can walk unassisted. People with the childhood-onset type usually develop muscle weakness in adolescence. The adult-onset type is the mildest of all the various types. People with this type usually develop muscle weakness between ages 20 and 50.","keywords":[]}
{"symbol":"DA2B1","name":"Distal arthrogryposis type 2B","alternate_names":["ARTHROGRYPOSIS, DISTAL, TYPE 2B1"],"id":"546","alternate_symbols":["DA2B","FSSV","SHS"],"medgen_id":"C1834523","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"601680\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1147\"}","{\"db\":\"OMIM\",\"id\":\"191043.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARTHROGRYPOSIS, DISTAL, TYPE 2B1\"}","{\"db\":\"OMIM\",\"id\":\"191043.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARTHROGRYPOSIS, DISTAL, TYPE 2B1\"}","{\"db\":\"OMIM\",\"id\":\"191043.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARTHROGRYPOSIS, DISTAL, TYPE 2B1\"}","{\"db\":\"OMIM\",\"id\":\"191043.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARTHROGRYPOSIS, DISTAL, TYPE 2B1\"}","{\"db\":\"OMIM\",\"id\":\"601680\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARTHROGRYPOSIS, DISTAL, TYPE 2B1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9909\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DA2B\"}","{\"db\":\"OMIM\",\"id\":\"601680\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FSSV\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9909\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FSSV\"}","{\"db\":\"OMIM\",\"id\":\"601680\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SHS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9909\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SHS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Arthrogryposis+Distal+Type+2B/597\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601680\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"name":"Dysplasia of acetabulum","alternate_names":["Congenital dislocation of the hip","Congenital dislocation of the hips","Congenital hip anomaly","Congenital hip dislocation","Congenital hip dislocations","Developmental dysplasia of the hip","Dislocated hip since birth","HIP DYSPLASIA, DEVELOPMENTAL"],"id":"36162","alternate_symbols":["CDH","DDH"],"medgen_id":"C0019555","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001374\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"PS142700\",\"type\":\"Phenotypic series\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001374\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital dislocation of the hip\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001374\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital dislocation of the hips\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001374\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital hip anomaly\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001374\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital hip dislocation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001374\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital hip dislocations\"}","{\"db\":\"OMIM\",\"id\":\"PS142700\",\"type\":\"Phenotypic series\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Developmental dysplasia of the hip\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001374\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dislocated hip since birth\"}","{\"db\":\"OMIM\",\"id\":\"142700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HIP DYSPLASIA, DEVELOPMENTAL\"}","{\"db\":\"OMIM\",\"id\":\"142700\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDH\"}","{\"db\":\"OMIM\",\"id\":\"142700\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DDH\"}","{\"db\":\"SNOMED CT\",\"id\":\"52781008\",\"ref_field\":\"name\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"FCHL3","name":"Hyperapobetalipoproteinemia","alternate_names":["Hyperlipidemia, familial combined"],"id":"2183","content":"{\"Citation\":[{\"@Abbrev\":\"ES, 2012\",\"@Type\":\"practice guideline\",\"ID\":[{\"$\":\"22962670\",\"@Source\":\"PubMed\"},{\"$\":\"3431581\",\"@Source\":\"pmc\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24921113\",\"@Source\":\"PubMed\"},{\"$\":\"NBK208534\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":["FCHL"],"medgen_id":"C0020474","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008158\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"144250\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperlipidemia%2C+familial+combined/8593\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperlipidemia, familial combined\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558516\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FCHL\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008158\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"144250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"name":"Keratitis-ichthyosis-deafness syndrome, autosomal dominant","alternate_names":[],"id":"2511","alternate_symbols":[],"medgen_id":"C0265336","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"148210\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"477\"}","{\"db\":\"Genetic Alliance\",\"id\":\"KID+syndrome/3992\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3113\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"keratitis-ichthyosis-deafness-syndrome\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Keratitis-ichthyosis-deafness (KID) syndrome is characterized by eye problems, skin abnormalities, and hearing loss.People with KID syndrome usually have keratitis, which is inflammation of the front surface of the eye (the cornea). The keratitis may cause pain, increased sensitivity to light (photophobia), abnormal blood vessel growth over the cornea (neovascularization), and scarring. Over time, affected individuals experience a loss of sharp vision (reduced visual acuity); in severe cases the keratitis can lead to blindness.Most people with KID syndrome have thick, hard skin on the palms of the hands and soles of the feet (palmoplantar keratoderma). Affected individuals also have thick, reddened patches of skin (erythrokeratoderma) that are dry and scaly (ichthyosis). These dry patches can occur anywhere on the body, although they most commonly affect the neck, groin, and armpits. Breaks in the skin often occur and may lead to infections. In severe cases these infections can be life-threatening, especially in infancy. Approximately 12 percent of people with KID syndrome develop a type of skin cancer called squamous cell carcinoma, which may also affect mucous membranes such as the lining of the mouth.Partial hair loss is a common feature of KID syndrome, and often affects the eyebrows and eyelashes. Affected individuals may also have small, abnormally formed nails.Hearing loss in this condition is usually profound, but occasionally is less severe.","keywords":[]}
{"symbol":"EDSDERMS","name":"Ehlers-Danlos syndrome dermatosparaxis type","alternate_names":["Dermatosparaxis","EDS VIIC","Ehlers-Danlos syndrome, type VII, autosomal recessive"],"id":"2073","content":"{\"Citation\":{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987428\",\"@Source\":\"pmc\"}}}","alternate_symbols":["EDS7C"],"medgen_id":"C2700425","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"225410\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1901\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ehlers-Danlos+Syndrome+Dermatosparaxis+Type/2485\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dermatosparaxis\"}","{\"db\":\"SNOMED CT\",\"id\":\"55711009\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dermatosparaxis\"}","{\"db\":\"OMIM\",\"id\":\"225410\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EDS VIIC\"}","{\"db\":\"OMIM\",\"id\":\"225410\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EDS7C\"}","{\"db\":\"OMIM\",\"id\":\"225410\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"name":"Anterior segment anomalies","alternate_names":["Abnormal anterior chamber morphology","Abnormality of the anterior chamber","Anterior chamber anomalies","Ocular anterior chamber abnormality"],"id":"10372","alternate_symbols":[],"medgen_id":"C3152182","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000593\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000593\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormal anterior chamber morphology\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000593\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormality of the anterior chamber\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000593\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Anterior chamber anomalies\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000593\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ocular anterior chamber abnormality\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"FBCG1","name":"Fibrochondrogenesis 1","alternate_names":[],"id":"5152","alternate_symbols":[],"medgen_id":"C3278138","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"228520\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2021\"}","{\"db\":\"GeneTests\",\"id\":\"3518\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"228520\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"228520\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"SMA","name":"Spinal muscular atrophy","alternate_names":["Spinal muscle degeneration","Spinal muscle wasting"],"id":"9569","content":"{\"Citation\":[{\"@Abbrev\":\"Int'l SCC for SMA, 2007\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"17761659\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301526\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1352\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110347\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACOG, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19384151\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C0026847","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007269\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007269\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spinal muscle degeneration\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007269\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spinal muscle wasting\"}","{\"db\":\"ADAM\",\"id\":\"CN038177\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spinal+muscular+atrophy/6729\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007269\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7674\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"5262007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1352\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507864\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Spinal muscular atrophy (SMA) is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal \u003e distal, and progressive. Before the genetic basis of SMA was understood, it was classified into clinical subtypes based on maximum motor function achieved; however, it is now apparent that the phenotype of SMN1-associated SMA spans a continuum without clear delineation of subtypes. With supportive care only, poor weight gain with growth failure, restrictive lung disease, scoliosis, and joint contractures are common complications; however, newly available targeted treatment options are changing the natural history of this disease.","keywords":[]}
{"symbol":"NEM6","name":"Nemaline myopathy 6","alternate_names":[],"id":"3441","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301465\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1288\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22510848\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C1836472","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"609273\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171439\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nemaline+myopathy+6/5128\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10114\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"609273\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10114\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"MCOPS4","name":"Microphthalmia syndromic 4","alternate_names":[],"id":"5531","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301694\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1521\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["ANOP1"],"medgen_id":"C1844948","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"301590\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"85275\"}","{\"db\":\"OMIM\",\"id\":\"301590\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ANOP1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia+syndromic+4/4788\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5066\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301590\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5066\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"CCD","name":"Myopathy, Central Core","alternate_names":["Central core disease"],"id":"865","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301565\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1391\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21989361\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22009146\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["CCO"],"medgen_id":"C0751951","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"117000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"597\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Central+Core+Disease/1190\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Central core disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"43152001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Central core disease\"}","{\"db\":\"OMIM\",\"id\":\"117000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CCO\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6014\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CCO\"}","{\"db\":\"OMIM\",\"id\":\"117000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6014\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":["Pharmacogenetic"]}
{"symbol":"NEM4","name":"Nemaline myopathy 4","alternate_names":[],"id":"3025","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301465\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1288\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22510848\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C1836447","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"609285\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nemaline+myopathy+4/5126\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10112\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"nemaline-myopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609285\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10112\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Nemaline myopathy is a disorder that primarily affects skeletal muscles, which are muscles that the body uses for movement. People with nemaline myopathy have muscle weakness (myopathy) throughout the body, but it is typically most severe in the muscles of the face; neck; trunk; and other muscles close to the center of the body (proximal muscles), such as those of the upper arms and legs. This weakness can worsen over time. Affected individuals may have feeding and swallowing difficulties, foot deformities, abnormal curvature of the spine (scoliosis), and joint deformities (contractures). Most people with nemaline myopathy are able to walk, although some affected children may begin walking later than usual. As the condition progresses, some people may require wheelchair assistance. In severe cases, the muscles used for breathing are affected and life-threatening breathing difficulties can occur.Nemaline myopathy is divided into six types. In order of decreasing severity, the types are: severe congenital, Amish, intermediate congenital, typical congenital, childhood-onset, and adult-onset. The types are distinguished by the age when symptoms first appear and the severity of symptoms; however, there is overlap among the various types. The severe congenital type is the most life-threatening. Most individuals with this type do not survive past early childhood due to respiratory failure. The Amish type solely affects the Old Order Amish population of Pennsylvania and is typically fatal in early childhood. The most common type of nemaline myopathy is the typical congenital type, which is characterized by muscle weakness and feeding problems beginning in infancy. Most of these individuals do not have severe breathing problems and can walk unassisted. People with the childhood-onset type usually develop muscle weakness in adolescence. The adult-onset type is the mildest of all the various types. People with this type usually develop muscle weakness between ages 20 and 50.","keywords":[]}
{"symbol":"LFS","name":"Li-Fraumeni syndrome 1","alternate_names":["Li-Fraumeni syndrome 3"],"id":"5406","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301471\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1294\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301488\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1311\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACS, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17392385\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2010\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"20065170\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2003\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"12692171\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2668639\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ASHG/ACMG, 1995\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"1801355\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_symbols":["LFS1","LFS3"],"medgen_id":"C1835398","type":"Disease","xrefs":["{\"db\":\"Gene\",\"id\":\"553989\"}","{\"db\":\"OMIM\",\"id\":\"151623\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"524\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6902\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LFS1\"}","{\"db\":\"OMIM\",\"id\":\"609266\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LFS3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Li-Fraumeni+syndrome+1/8745\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1311\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"151623\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is ≥70% for men and ≥90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.","keywords":[]}
{"symbol":"POF1","name":"Premature ovarian failure 1","alternate_names":["FMR1-Related Primary Ovarian Insufficiency","HYPERGONADOTROPIC OVARIAN FAILURE, X-LINKED","PREMATURE OVARIAN FAILURE, X-LINKED","Primary ovarian insufficiency, fragile X-associated"],"id":"3532","content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22797890\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EMQN, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25227148\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["POFX"],"medgen_id":"C4552079","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERGONADOTROPIC OVARIAN FAILURE, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PREMATURE OVARIAN FAILURE, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"POFX\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fragile-x-associated-primary-ovarian-insufficiency\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Fragile X-associated primary ovarian insufficiency (FXPOI) is a condition that affects women and is characterized by reduced function of the ovaries. The ovaries are the female reproductive organs in which egg cells are produced. As a form of primary ovarian insufficiency, FXPOI can cause irregular menstrual cycles, early menopause, an inability to have children (infertility), and elevated levels of a hormone known as follicle stimulating hormone (FSH). FSH is produced in both males and females and helps regulate the development of reproductive cells (eggs in females and sperm in males). In females, the level of FSH rises and falls, but overall it increases as a woman ages. In younger women, elevated levels may indicate early menopause and fertility problems.The severity of FXPOI is variable. The most severely affected women have overt POI (formerly called premature ovarian failure). These women have irregular or absent menstrual periods and elevated FSH levels before age 40. Overt POI often causes infertility. Other women have occult POI; they have normal menstrual periods but reduced fertility, and they may have elevated levels of FSH (in which case, it is called biochemical POI). The reduction in ovarian function caused by FXPOI results in low levels of the hormone estrogen, which leads to many of the common signs and symptoms of menopause, such as hot flashes, insomnia, and thinning of the bones (osteoporosis). Women with FXPOI undergo menopause an average of 5 years earlier than women without the condition.","keywords":[]}
{"name":"APOE5 VARIANT","alternate_names":["Hypercholesterolemia and hypertriglyceridemia, type III"],"id":"12920","alternate_symbols":[],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"107741.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"107741.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"MCOPS9","name":"Microphthalmia syndromic 9","alternate_names":["ANOPHTHALMIA, CLINICAL, WITH MILD FACIAL DYSMORPHISM AND VARIABLE MALFORMATIONS OF THE LUNG, HEART, AND DIAPHRAGM","PULMONARY AGENESIS, MICROPHTHALMIA, AND DIAPHRAGMATIC DEFECT","PULMONARY HYPOPLASIA-DIAPHRAGMATIC HERNIA-ANOPHTHALMIA-CARDIAC DEFECT"],"id":"5533","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["PDAC","PMD"],"medgen_id":"C1832661","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2470\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANOPHTHALMIA, CLINICAL, WITH MILD FACIAL DYSMORPHISM AND VARIABLE MALFORMATIONS OF THE LUNG, HEART, AND DIAPHRAGM\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY AGENESIS, MICROPHTHALMIA, AND DIAPHRAGMATIC DEFECT\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY HYPOPLASIA-DIAPHRAGMATIC HERNIA-ANOPHTHALMIA-CARDIAC DEFECT\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PDAC\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PMD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia+syndromic+9/4793\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"713\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"713\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"FXTAS","name":"Fragile X tremor/ataxia syndrome","alternate_names":["Fragile X-Associated Tremor/Ataxia Syndrome"],"id":"1831","content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22797890\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301558\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1384\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110344\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110946\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111547\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21540884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EMQN, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25227148\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23765048\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C1839780","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"300623\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93256\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fragile+X-Associated+Tremor+Ataxia+Syndrome/2910\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1384\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300623\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"FMR1 disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI). Fragile X syndrome occurs in individuals with an FMR1 full mutation or other loss-of-function variant and is nearly always characterized in affected males by developmental delay and intellectual disability along with a variety of behavioral issues. Autism spectrum disorder is present in 50%-70% of individuals with FXS. Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media. Adults may have mitral valve prolapse or aortic root dilatation. The physical and behavioral features seen in males with FXS have been reported in females heterozygous for the FMR1 full mutation, but with lower frequency and milder involvement. FXTAS occurs in individuals who have an FMR1 premutation and is characterized by late-onset, progressive cerebellar ataxia and intention tremor followed by cognitive impairment. Psychiatric disorders are common. Age of onset is typically between 60 and 65 years and is more common among males who are hemizygous for the premutation (40%) than among females who are heterozygous for the premutation (16%-20%). FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population.","keywords":[]}
{"name":"Rothmund-Thomson syndrome","alternate_names":[],"id":"4358","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301415\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1237\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["RTS"],"medgen_id":"C0032339","type":"Disease","xrefs":["{\"db\":\"Orphanet\",\"id\":\"2909\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4392\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RTS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rothmund+Thomson+syndrome/6363\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"rothmund-thomson-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"69093006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1237\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Rothmund-Thomson syndrome (RTS) is characterized by a rash that progresses to poikiloderma; sparse hair, eyelashes, and/or eyebrows; small size; skeletal and dental abnormalities; cataracts; and an increased risk for cancer, especially osteosarcoma. The skin is typically normal at birth; the rash of RTS develops between ages three and six months as erythema, swelling, and blistering on the face, subsequently spreading to the buttocks and extremities. The rash evolves over months to years into the chronic pattern of reticulated hypo- and hyperpigmentation, punctate atrophy, and telangiectasias, collectively known as poikiloderma. Hyperkeratotic lesions occur in approximately one third of individuals. Skeletal abnormalities include radial ray defects, ulnar defects, absent or hypoplastic patella, and osteopenia.","keywords":[]}
{"symbol":"CHDS5","name":"Coronary heart disease 5","alternate_names":["CORONARY ARTERY DISEASE, EARLY-ONSET","CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5"],"id":"1571","alternate_symbols":[],"medgen_id":"C1837173","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"608901\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"608901\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CORONARY ARTERY DISEASE, EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"608901\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Coronary+heart+disease+5/8093\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608901\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"MCOPS2","name":"Oculofaciocardiodental syndrome","alternate_names":[],"id":"2945","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301694\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1521\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":[],"medgen_id":"C1846265","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"300166\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2712\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia+syndromic+2/4786\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4628\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"oculofaciocardiodental-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300166\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4628\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Oculofaciocardiodental (OFCD) syndrome is a condition that affects the development of the eyes (oculo-), facial features (facio-), heart (cardio-) and teeth (dental). This condition occurs only in females.The eye abnormalities associated with OFCD syndrome can affect one or both eyes. Many people with this condition are born with eyeballs that are abnormally small (microphthalmia). Other eye problems can include clouding of the lens (cataract) and a higher risk of glaucoma, an eye disease that increases the pressure in the eye. These abnormalities can lead to vision loss or blindness.People with OFCD syndrome often have a long, narrow face with distinctive facial features, including deep-set eyes and a broad nasal tip that is divided by a cleft. Some affected people have an opening in the roof of the mouth called a cleft palate.Heart defects are another common feature of OFCD syndrome. Babies with this condition may be born with a hole between two chambers of the heart (an atrial or ventricular septal defect) or a leak in one of the valves that controls blood flow through the heart (mitral valve prolapse).Teeth with very large roots (radiculomegaly) are characteristic of OFCD syndrome. Additional dental abnormalities can include delayed loss of primary (baby) teeth, missing or abnormally small teeth, misaligned teeth, and defective tooth enamel.","keywords":[]}
{"name":"APOE4 VARIANT","alternate_names":[],"id":"12924","alternate_symbols":[],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"107741.0028\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"HIES1","name":"Hyper-IgE recurrent infection syndrome 1, autosomal dominant","alternate_names":["Autosomal Dominant Hyper IgE Syndrome","Job's Syndrome"],"id":"2348","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301786\",\"@Source\":\"PubMed\"},{\"$\":\"NBK25507\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["AD-HIES","HIES"],"medgen_id":"C4721531","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"147060\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2314\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK25507\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Autosomal Dominant Hyper IgE Syndrome\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6800\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AD-HIES\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK25507\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"147060\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Autosomal dominant hyper IgE syndrome (AD-HIES) is a primary immune deficiency characterized by the classic triad of recurrent skin boils, cyst-forming pneumonias, and extreme elevations of serum IgE. It is now recognized that other common manifestations include eczema, mucocutaneous candidiasis, and several connective tissue and skeletal abnormalities. A rash in the newborn period subsequently evolves into an eczematoid dermatitis. Recurrent staphylococcal skin boils and bacterial pneumonias usually manifest in the first years of life. Pneumatocoeles and bronchiectasis often result from aberrant healing of pneumonias. Mucocutaneous candidiasis is common. A characteristic facial appearance typically emerges in adolescence. Skeletal abnormalities include osteopenia, minimal trauma fractures, and scoliosis. Vascular abnormalities include middle-sized artery tortuosity and aneurysms, with infrequent clinical sequelae of myocardial infarction and subarachnoid hemorrhage. Gastrointestinal (GI) manifestations include gastroesophageal reflux disease; esophageal dysmotility; and rarely colonic perforations, some of which are associated with diverticuli. Fungal infection of the GI tract (typically histoplasmosis, Cryptococcus, and Coccidioides) also occur infrequently. Survival is typically into adulthood, but life span is often shortened. Most deaths are associated with Gram-negative (Pseudomonas) or filamentous fungal pneumonias resulting in hemoptysis. Lymphomas occur at an increased frequency.","keywords":[]}
{"symbol":"GHIP","name":"Short stature, idiopathic, autosomal","alternate_names":["GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL","GROWTH HORMONE INSENSITIVITY, PARTIAL","Short Stature"],"id":"4141","alternate_symbols":["SS"],"medgen_id":"C1858656","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"604271\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314802\"}","{\"db\":\"Orphanet\",\"id\":\"314811\"}","{\"db\":\"OMIM\",\"id\":\"601898.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"601898.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"601898.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"615925\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"604271\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Short+stature%2C+idiopathic%2C+autosomal/9295\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604271\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"LFS","name":"Li-Fraumeni syndrome","alternate_names":["Sarcoma family syndrome of Li and Fraumeni"],"id":"10539","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301488\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1311\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACS, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17392385\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C0085390","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS151623\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"524\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"li-fraumeni-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"428850001\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1311\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is ≥70% for men and ≥90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.","keywords":[]}
{"symbol":"NEM1","name":"Nemaline myopathy 1","alternate_names":[],"id":"3163","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301465\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1288\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22510848\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C1836448","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"609284\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171433\"}","{\"db\":\"Orphanet\",\"id\":\"171439\"}","{\"db\":\"Orphanet\",\"id\":\"171881\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nemaline+myopathy+1/5123\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7171\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"609284\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7171\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"SCA6","name":"Spinocerebellar ataxia 6","alternate_names":[],"id":"4438","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301319\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1140\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C0752124","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"183086\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98758\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spinocerebellar+ataxia+6/6767\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10351\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1140\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"183086\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10351\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Spinocerebellar ataxia type 6 (SCA6) is characterized by adult-onset, slowly progressive cerebellar ataxia, dysarthria, and nystagmus. The age of onset ranges from 19 to 73 years; mean age of onset is between 43 and 52 years. Initial symptoms are gait unsteadiness, stumbling, and imbalance (in ~90%) and dysarthria (in ~10%). Eventually all persons have gait ataxia, upper-limb incoordination, intention tremor, and dysarthria. Dysphagia and choking are common. Visual disturbances may result from diplopia, difficulty fixating on moving objects, horizontal gaze-evoked nystagmus, and vertical nystagmus. Hyperreflexia and extensor plantar responses occur in up to 40%-50%. Basal ganglia signs, including dystonia and blepharospasm, occur in up to 25%. Mentation is generally preserved.","keywords":[]}
{"symbol":"RTS1","name":"Rothmund-Thomson syndrome type 1","alternate_names":["POIKILODERMA ATROPHICANS AND CATARACT"],"id":"43000","alternate_symbols":[],"medgen_id":"CN262442","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"618625\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"221008\"}","{\"db\":\"OMIM\",\"id\":\"618625\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"POIKILODERMA ATROPHICANS AND CATARACT\"}","{\"db\":\"OMIM\",\"id\":\"618625\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"MCOPS1","name":"Lenz microphthalmia syndrome","alternate_names":[],"id":"2799","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301694\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1521\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":["MAA","NAA10"],"medgen_id":"C0796016","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"568\"}","{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MAA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia+syndromic+1/4784\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"lenz-microphthalmia-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"87\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"438504004\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"87\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"STSL1","name":"Sitosterolemia","alternate_names":["SITOSTEROLEMIA 1"],"id":"3731","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23556150\",\"@Source\":\"PubMed\"},{\"$\":\"NBK131810\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["STSL"],"medgen_id":"C0342907","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"210250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2882\"}","{\"db\":\"OMIM\",\"id\":\"210250\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"605460.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SITOSTEROLEMIA 1\"}","{\"db\":\"OMIM\",\"id\":\"210250\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"STSL\"}","{\"db\":\"GeneTests\",\"id\":\"3093\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Sitosterolemia/6620\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7653\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"238104009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK131810\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"210250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Sitosterolemia is characterized by: Tendon xanthomas or tuberous (i.e., planar) xanthomas that can occur in childhood and in unusual locations (heels, knees, elbows, and buttocks); Premature atherosclerosis that can lead to angina, aortic valve involvement, myocardial infarction, and sudden death; Hemolytic anemia, abnormally shaped erythrocytes (stomatocytes), and large platelets (macrothrombocytopenia). On occasion, the abnormal hematologic findings may be the initial presentation. The phenotypic spectrum of sitosterolemia is probably not fully appreciated due to underdiagnosis and the fact that clinical findings in infants are likely to be highly dependent on diet.","keywords":[]}
{"symbol":"NEM2","name":"Nemaline myopathy 2","alternate_names":[],"id":"5618","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301465\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1288\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22510848\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C1850569","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"256030\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nemaline+myopathy+2/5124\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8335\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"256030\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8335\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"MCOPCB5","name":"Microphthalmia, isolated, with coloboma 5","alternate_names":[],"id":"2797","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C1968843","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"611638\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98938\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia%2C+isolated%2C+with+coloboma+5/8881\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611638\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"MCOP2","name":"Microphthalmia, isolated 2","alternate_names":["ANOPHTHALMIA, CLINICAL, ISOLATED"],"id":"2792","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C1864720","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"610093\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2542\"}","{\"db\":\"OMIM\",\"id\":\"610093\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANOPHTHALMIA, CLINICAL, ISOLATED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia%2C+isolated+2/8873\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"microphthalmia\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610093\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Microphthalmia is an eye abnormality that arises before birth. In this condition, one or both eyeballs are abnormally small. In some affected individuals, the eyeball may appear to be completely missing; however, even in these cases some remaining eye tissue is generally present. Such severe microphthalmia should be distinguished from another condition called anophthalmia, in which no eyeball forms at all. However, the terms anophthalmia and severe microphthalmia are often used interchangeably. Microphthalmia may or may not result in significant vision loss.People with microphthalmia may also have a condition called coloboma. Colobomas are missing pieces of tissue in structures that form the eye. They may appear as notches or gaps in the colored part of the eye called the iris; the retina, which is the specialized light-sensitive tissue that lines the back of the eye; the blood vessel layer under the retina called the choroid; or in the optic nerves, which carry information from the eyes to the brain. Colobomas may be present in one or both eyes and, depending on their size and location, can affect a person's vision.People with microphthalmia may also have other eye abnormalities, including clouding of the lens of the eye (cataract) and a narrowed opening of the eye (narrowed palpebral fissure). Additionally, affected individuals may have an abnormality called microcornea, in which the clear front covering of the eye (cornea) is small and abnormally curved.Between one-third and one-half of affected individuals have microphthalmia as part of a syndrome that affects other organs and tissues in the body. These forms of the condition are described as syndromic. When microphthalmia occurs by itself, it is described as nonsyndromic or isolated.","keywords":[]}
{"symbol":"AT","name":"Ataxia-telangiectasia syndrome","alternate_names":["AT, COMPLEMENTATION GROUP C","ATAXIA-TELANGIECTASIA, COMPLEMENTATION GROUP A","ATAXIA-TELANGIECTASIA, FRESNO VARIANT","Ataxia-telangiectasia","Ataxia-telangiectasia, complementation group D","Ataxia-telangiectasia, complementation group E","Cerebello-oculocutaneous telangiectasia","Immunodeficiency with ataxia telangiectasia","Louis-Bar syndrome"],"id":"4635","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301790\",\"@Source\":\"PubMed\"},{\"$\":\"NBK26468\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["A-T","AT1","ATA","ATC","ATD","ATE","ATM"],"medgen_id":"C0004135","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"208900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"100\"}","{\"db\":\"OMIM\",\"id\":\"208900\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AT, COMPLEMENTATION GROUP C\"}","{\"db\":\"OMIM\",\"id\":\"607585.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ATAXIA-TELANGIECTASIA, COMPLEMENTATION GROUP A\"}","{\"db\":\"OMIM\",\"id\":\"607585.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ATAXIA-TELANGIECTASIA, FRESNO VARIANT\"}","{\"db\":\"OMIM\",\"id\":\"208900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AT1\"}","{\"db\":\"OMIM\",\"id\":\"208900\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ATA\"}","{\"db\":\"OMIM\",\"id\":\"208900\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ATC\"}","{\"db\":\"OMIM\",\"id\":\"208900\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ATD\"}","{\"db\":\"OMIM\",\"id\":\"208900\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ATE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ataxia+Telangiectasia/637\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"68504005\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"208900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5862\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":["Hereditary cancer syndrome"]}
{"symbol":"FANCC","name":"Fanconi anemia, complementation group C","alternate_names":["FACC","FANCONI PANCYTOPENIA, TYPE 3"],"id":"10927","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301575\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1401\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301753\",\"@Source\":\"PubMed\"},{\"$\":\"NBK5192\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"18197057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACOG, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19888064\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"FARF, 2008\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management, 2008\"},\"URL\":{\"$\":\"http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf\"}}]}","alternate_symbols":["FA3","FAC"],"medgen_id":"C3468041","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"227645\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"84\"}","{\"db\":\"OMIM\",\"id\":\"227645\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FACC\"}","{\"db\":\"OMIM\",\"id\":\"227645\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FANCONI PANCYTOPENIA, TYPE 3\"}","{\"db\":\"OMIM\",\"id\":\"227645\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FA3\"}","{\"db\":\"OMIM\",\"id\":\"227645\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FAC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fanconi+Anemia+Type+3/2783\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1401\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"227645\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, gastrointestinal tract, and genitourinary tract – are more common in individuals with FA.","keywords":["Neoplasm"]}
{"name":"Mucolipidosis III Gamma","alternate_names":["ML III GAMMA","ML IIIC","MUCOLIPIDOSIS III, COMPLEMENTATION GROUP C","MUCOLIPIDOSIS III, IRANIAN VARIANT FORM","MUCOLIPIDOSIS III, VARIANT FORM"],"id":"3219","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301784\",\"@Source\":\"PubMed\"},{\"$\":\"NBK24701\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C1854896","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"252605\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"423470\"}","{\"db\":\"Orphanet\",\"id\":\"577\"}","{\"db\":\"OMIM\",\"id\":\"252605\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ML III GAMMA\"}","{\"db\":\"OMIM\",\"id\":\"252605\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ML IIIC\"}","{\"db\":\"OMIM\",\"id\":\"252605\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUCOLIPIDOSIS III, COMPLEMENTATION GROUP C\"}","{\"db\":\"OMIM\",\"id\":\"252605\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUCOLIPIDOSIS III, IRANIAN VARIANT FORM\"}","{\"db\":\"OMIM\",\"id\":\"252605\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUCOLIPIDOSIS III, VARIANT FORM\"}","{\"db\":\"GeneTests\",\"id\":\"275242\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mucolipidosis+III+Gamma/8910\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK24701\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Mucolipidosis III gamma (ML IIIγ) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues. Clinical onset is in early childhood; the progressive course results in severe functional impairment and significant morbidity from chronic pain. Cardiorespiratory complications (restrictive lung disease from thoracic involvement, and thickening and insufficiency of the mitral and aortic valves) are rarely clinically significant. A few (probably \u003c10%) affected individuals display mild cognitive impairment.","keywords":[]}
{"symbol":"SPGF39","name":"SPERMATOGENIC FAILURE 39","alternate_names":[],"id":"43033","alternate_symbols":[],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"618643\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"610063.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610063.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610063.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610063.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618643\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618643\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"SOD","name":"Septo-optic dysplasia sequence","alternate_names":["Septo-optic dysplasia"],"id":"4135","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["HESX1"],"medgen_id":"C0338503","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100842\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"182230\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3157\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100842\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Septo-optic dysplasia\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Septo-optic+dysplasia+sequence/9284\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"7611002\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7627\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"name":"Eczema","alternate_names":["Eczematous rash"],"id":"17297","alternate_symbols":[],"medgen_id":"C0013595","type":"Finding","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000964\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001481\",\"type\":\"secondary\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Eczema/9652\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000964\",\"ref_field\":\"name\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"NEM8","name":"Nemaline myopathy 8","alternate_names":[],"id":"18191","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301465\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1288\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C3809209","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"615348\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171430\"}","{\"db\":\"OMIM\",\"id\":\"615348\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"name":"Hyperekplexia","alternate_names":[],"id":"10190","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301437\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1260\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C0234166","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS149400\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"306773\"}","{\"db\":\"GeneTests\",\"id\":\"74148\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS149400\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1260\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Hereditary hyperekplexia (HPX) is characterized by generalized stiffness immediately after birth that normalizes during the first years of life; excessive startle reflex (eye blinking and a flexor spasm of the trunk) to unexpected (particularly auditory) stimuli; and a short period of generalized stiffness following the startle response during which voluntary movements are impossible. Exaggerated head-retraction reflex (HRR) consisting of extension of the head followed by violent flexor spasms of limbs and neck muscles elicited by tapping the tip of the nose is observed in most children. Other findings include periodic limb movements in sleep (PLMS) and hypnagogic (occurring when falling asleep) myoclonus. Sudden infant death (SIDS) has been reported. Intellect is usually normal; mild intellectual disability may occur.","keywords":[]}
{"symbol":"GSD6","name":"Glycogen storage disease, type VI","alternate_names":["GSD VI","Hepatic glycogen phosphorylase deficiency"],"id":"10922","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301760\",\"@Source\":\"PubMed\"},{\"$\":\"NBK5941\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C0017925","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"232700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"369\"}","{\"db\":\"OMIM\",\"id\":\"232700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GSD VI\"}","{\"db\":\"SNOMED CT\",\"id\":\"237971004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hepatic glycogen phosphorylase deficiency\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Glycogen+Storage+Disease+Type+6/3126\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"29291001\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK5941\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"232700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6529\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Glycogen storage disease type VI (GSD VI) is a disorder of glycogenolysis caused by deficiency of hepatic glycogen phosphorylase. This critical enzyme catalyzes the rate-limiting step in glycogen degradation, and deficiency of the enzyme in the untreated child is characterized by hepatomegaly, poor growth, ketotic hypoglycemia, elevated hepatic transaminases, hyperlipidemia, and low prealbumin level. GSD VI is usually a relatively mild disorder that presents in infancy and childhood; rare cases of more severe disease manifesting with recurrent hypoglycemia and marked hepatomegaly have been described. More common complications in the setting of suboptimal metabolic control include short stature, delayed puberty, osteopenia, and osteoporosis. Hepatic fibrosis commonly develops in GSD VI, but cirrhosis and hypertrophic cardiomyopathy are rare. Clinical and biochemical abnormalities may decrease with age, but ketosis and hypoglycemia can continue to occur.","keywords":[]}
{"name":"NEURODEGENERATION, EARLY-ONSET, WITH CHOREOATHETOSIS AND MICROCYTIC ANEMIA","alternate_names":[],"id":"41782","alternate_symbols":[],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"147582.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"147582.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"147582.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"147582.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"MCOPCB3","name":"Microphthalmia, isolated, with coloboma 3","alternate_names":["MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 3"],"id":"2795","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C1864721","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"610092\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98938\"}","{\"db\":\"OMIM\",\"id\":\"610092\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia%2C+isolated%2C+with+coloboma+3/8880\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610092\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"TGD","name":"Tangier disease","alternate_names":["Cholesterol thesaurismosis"],"id":"6024","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31751110\",\"@Source\":\"PubMed\"},{\"$\":\"NBK549920\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["HDLDT1"],"medgen_id":"C0039292","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"205400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"31150\"}","{\"db\":\"OMIM\",\"id\":\"205400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HDLDT1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7731\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HDLDT1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Tangier+disease/6997\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"tangier-disease\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7731\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK549920\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"205400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Tangier disease is characterized by severe deficiency or absence of high-density lipoprotein (HDL) in the circulation resulting in tissue accumulation of cholesteryl esters throughout the body, particularly in the reticuloendothelial system. The major clinical signs of Tangier disease include hyperplastic yellow-orange tonsils, hepatosplenomegaly, and peripheral neuropathy, which may be either relapsing-remitting or chronic progressive in nature. Rarer complications may include corneal opacities that typically do not affect vision, premature atherosclerotic coronary artery disease occurring in the sixth and seventh decades of life (not usually before age 40 years), and mild hematologic manifestations, such as mild thrombocytopenia, reticulocytosis, stomatocytosis, or hemolytic anemia. The clinical expression of Tangier disease is variable, with some affected individuals only showing biochemical perturbations.","keywords":[]}
{"symbol":"STHE","name":"Hyperekplexia 1","alternate_names":["HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT","HYPEREKPLEXIA 1, AUTOSOMAL RECESSIVE","Hyperekplexia hereditary"],"id":"2177","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301437\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1260\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["HKPX1"],"medgen_id":"C4551954","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"149400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3197\"}","{\"db\":\"OMIM\",\"id\":\"138491.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"138491.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"138491.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"138491.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"138491.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"138491.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"138491.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperekplexia+hereditary/3551\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperekplexia hereditary\"}","{\"db\":\"OMIM\",\"id\":\"149400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HKPX1\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1260\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"149400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3129\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Hereditary hyperekplexia (HPX) is characterized by generalized stiffness immediately after birth that normalizes during the first years of life; excessive startle reflex (eye blinking and a flexor spasm of the trunk) to unexpected (particularly auditory) stimuli; and a short period of generalized stiffness following the startle response during which voluntary movements are impossible. Exaggerated head-retraction reflex (HRR) consisting of extension of the head followed by violent flexor spasms of limbs and neck muscles elicited by tapping the tip of the nose is observed in most children. Other findings include periodic limb movements in sleep (PLMS) and hypnagogic (occurring when falling asleep) myoclonus. Sudden infant death (SIDS) has been reported. Intellect is usually normal; mild intellectual disability may occur.","keywords":[]}
{"symbol":"VAIHS","name":"Polyarteritis nodosa, childhoood-onset","alternate_names":["VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME"],"id":"6159","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31393689\",\"@Source\":\"PubMed\"},{\"$\":\"NBK544951\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["DADA2","PAN"],"medgen_id":"C3887654","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"404553\"}","{\"db\":\"OMIM\",\"id\":\"607575.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"607575.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DADA2\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PAN\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7360\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PAN\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK544951\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Adenosine deaminase 2 deficiency (DADA2) is a complex systemic autoinflammatory disorder in which vasculopathy/vasculitis, dysregulated immune function, and/or hematologic abnormalities may predominate. Inflammatory features include intermittent fevers, rash (often livedo racemosa/reticularis), and musculoskeletal involvement (myalgia/arthralgia, arthritis, myositis). Vasculitis, which usually begins before age ten years, may manifest as early-onset ischemic (lacunar) and/or hemorrhagic strokes, or as cutaneous or systemic polyarteritis nodosa. Hypertension and hepatosplenomegaly are often found. More severe involvement may lead to progressive central neurologic deficits (dysarthria, ataxia, cranial nerve palsies, cognitive impairment) or to ischemic injury to the kidney, intestine, and/or digits. Dysregulation of immune function can lead to immunodeficiency or autoimmunity of varying severity; lymphadenopathy may be present and some affected individuals have had lymphoproliferative disease. Hematologic disorders may begin early in life or in late adulthood, and can include lymphopenia, neutropenia, pure red cell aplasia, thrombocytopenia, or pancytopenia. Of note, both interfamilial and intrafamilial phenotypic variability (e.g., in age of onset, frequency and severity of manifestations) can be observed; also, individuals with biallelic ADA2 pathogenic variants may remain asymptomatic until adulthood or may never develop clinical manifestations of DADA2.","keywords":[]}
{"symbol":"CF","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Cystic fibrosis","alternate_names":[],"id":"1695","content":"{\"Citation\":[{\"@Abbrev\":\"ACMG/ACOG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11280952\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110945\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301428\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1250\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACOG, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19888064\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15789152\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110977\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"CPGPT/CF FPT Committees, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20675678\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ECFS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20605539\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19914445\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19914443\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG ACT Sheets, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21938795\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG Lab QA, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12394352\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CDC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22475884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Accurso et al., 2010\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"3148255\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACOG, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21422883\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CPIC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"4026598\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NSGC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24014130\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"HGS Australasia, 2014\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"25431289\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Wainwright et al., 2015\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"25981758\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17761616\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"DailyMed Drug Label, 2012\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"DailyMed Drug Label, KALYDECO, 2012\"},\"URL\":{\"$\":\"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25\"}}]}","alternate_symbols":[],"medgen_id":"C0010674","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"586\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004176\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000005248\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000025280\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000074114\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000194834\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000209428\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226639\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000277984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000288561\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320929\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000324499\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000328569\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330969\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332363\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501211\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501918\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501920\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501921\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502992\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505699\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506511\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507003\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507006\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507864\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507950\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508782\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508810\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508811\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508812\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508889\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508890\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508893\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508894\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514611\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515757\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515758\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520059\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521501\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521905\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528606\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529460\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556535\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556536\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558875\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558928\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568279\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569406\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569426\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569602\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cystic+Fibrosis/2071\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6233\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"190905008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1250\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6233\",\"ref_field\":\"symbol\"}"],"attribute_content":["{\"Attribute\":{\"$\":\"More than 1,000 CFTR variants have been reported.  Most common pathogenic variant is p.Phe508del.\",\"@Type\":\"disease mechanism\"}}"],"public_definition":"Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus occurs at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile. Congenital absence of the vas deferens (CAVD) is generally identified during evaluation of infertility or as an incidental finding at the time of a surgical procedure. Hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. Testicular development and function and spermatogenesis are usually normal.","keywords":[]}
{"symbol":"NF1","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Neurofibromatosis, type 1","alternate_names":["NEUROFIBROMATOSIS, PERIPHERAL TYPE","NEUROFIBROMATOSIS, TYPE I","NEUROFIBROMATOSIS, TYPE I, SOMATIC","Neurofibromatosis-Noonan syndrome"],"id":"5630","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301288\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1109\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301471\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1294\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ASCO, 2010\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"20065170\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASHG/ACMG, 1995\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"1801355\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NSGC, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17636453\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111019\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ES, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24893135\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NANETS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3419007\",\"@Source\":\"pmc\"}}]}","alternate_symbols":[],"medgen_id":"C0027831","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"162200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"636\"}","{\"db\":\"OMIM\",\"id\":\"162200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, PERIPHERAL TYPE\"}","{\"db\":\"OMIM\",\"id\":\"162200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0022\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0023\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0024\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0029\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0030\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0031\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0032\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0037\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0038\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0040\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0041\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0042\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0043\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0044\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0046\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"613113.0026\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"613113.0027\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS, TYPE I, SOMATIC\"}","{\"db\":\"Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia,Universidade Católica de Brasília\",\"id\":\"R34\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neurofibromatosis-Noonan syndrome\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260605\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000333054\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000335545\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500115\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500672\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500881\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500970\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500971\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500972\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501087\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501088\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509686\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510677\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510679\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511186\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511188\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514608\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514913\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514981\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515566\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520393\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520410\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521505\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521546\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528459\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528533\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528913\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529068\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551630\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552183\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552305\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556576\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561868\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562234\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562235\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568134\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568167\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neurofibromatosis+type+1/5174\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"92824003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1109\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"162200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7866\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Neurofibromatosis 1 (NF1) is characterized by multiple café au lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas, iris Lisch nodules, and choroidal freckling. About half of people with NF1 have plexiform neurofibromas, but most are internal and not suspected clinically. Learning disabilities are present in at least 50% of individuals with NF1. Less common but potentially more serious manifestations include optic nerve and other central nervous system gliomas, malignant peripheral nerve sheath tumors, scoliosis, tibial dysplasia, and vasculopathy.","keywords":["Hereditary cancer syndrome","Neoplasm"]}
{"symbol":"RDPA","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Phytanic acid storage disease","alternate_names":["HMSN IV","REFSUM DISEASE, ADULT, 1","REFSUM DISEASE, CLASSIC"],"id":"5851","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301527\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1353\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["HMSN4"],"medgen_id":"C0034960","type":"Disease","xrefs":["{\"db\":\"Gene\",\"id\":\"8024\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"773\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN IV\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"REFSUM DISEASE, ADULT, 1\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"REFSUM DISEASE, CLASSIC\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN4\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004880\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318975\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506571\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506572\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515436\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515763\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515765\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525961\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553865\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561876\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569521\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phytanic+acid+storage+disease/9107\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Refsum+disease+with+increased+pipecolic+acidemia/6182\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"25362006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1353\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600964\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4371\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Refsum disease is characterized by anosmia and early-onset retinitis pigmentosa, which are both universal findings with variable combinations of neuropathy, deafness, ataxia, and ichthyosis. Onset of symptoms ranges from age seven months to older than age 50 years. Cardiac arrhythmia and heart failure caused by cardiomyopathy are potentially severe health problems that develop later in life.","keywords":[]}
{"symbol":"FSNF","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Neurofibromatosis, familial spinal","alternate_names":[],"id":"3170","alternate_symbols":["NF1"],"medgen_id":"C1834235","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"162210\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"636\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501088\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507954\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528459\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552305\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neurofibromatosis%2C+familial+spinal/8999\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"162210\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":["Neoplasm"]}
{"symbol":"NF2","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Neurofibromatosis, type 2","alternate_names":[],"id":"3089","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301380\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1201\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_symbols":["ACN","BANF"],"medgen_id":"C0027832","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"101000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"637\"}","{\"db\":\"OMIM\",\"id\":\"101000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACN\"}","{\"db\":\"OMIM\",\"id\":\"101000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BANF\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000324942\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000335543\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000335548\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500116\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510681\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511190\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514608\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520026\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521547\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522559\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528460\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528652\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528909\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551653\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551659\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552305\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552306\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552308\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neurofibromatosis+type+2/5175\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"92503002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1201\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"101000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Neurofibromatosis 2 (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction. The average age of onset is 18 to 24 years. Almost all affected individuals develop bilateral vestibular schwannomas by age 30 years. Affected individuals may also develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and, very rarely, astrocytomas. Because NF2 is considered an adult-onset disease, it may be underrecognized in children, in whom skin tumors and ocular findings (retinal hamartoma, thickened optic nerves, cortical wedge cataracts, third cranial nerve palsy) may be the first manifestations. Mononeuropathy that occurs in childhood is an increasingly recognized finding; it frequently presents as a persistent facial palsy or hand/foot drop.","keywords":["Hereditary cancer syndrome","Neoplasm"]}
{"symbol":"NFNS","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Neurofibromatosis-Noonan syndrome","alternate_names":["NEUROFIBROMATOSIS TYPE 1"],"id":"15893","alternate_symbols":["NF1"],"medgen_id":"C2931482","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"601321\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"638\"}","{\"db\":\"OMIM\",\"id\":\"613113.0036\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROFIBROMATOSIS TYPE 1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327662\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501087\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506067\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507954\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514981\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521402\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528459\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552305\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neurofibromatosis-Noonan+syndrome/5181\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"372\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601321\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"372\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"keywords":[]}
{"symbol":"LGSS","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Legius syndrome","alternate_names":[],"id":"5389","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20945555\",\"@Source\":\"PubMed\"},{\"$\":\"NBK47312\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["NFLS","SPRED1"],"medgen_id":"C1969623","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"611431\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"137605\"}","{\"db\":\"OMIM\",\"id\":\"611431\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NFLS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327662\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500115\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500881\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501087\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501089\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501564\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506067\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509019\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509021\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511089\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514608\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514882\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515566\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519366\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519383\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519384\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520039\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520040\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528461\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551628\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551630\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561717\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562237\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562238\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562242\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568134\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568167\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Legius+syndrome/4153\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"legius-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10714\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK47312\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611431\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Legius syndrome is characterized by multiple café au lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1 (NF1). Additional clinical manifestations reported commonly include intertriginous freckling, lipomas, macrocephaly, and learning disabilities / ADHD / developmental delays. Current knowledge of the natural history of Legius syndrome is based on the clinical manifestations of fewer than 200 individuals with a molecularly confirmed diagnosis; better delineation of the clinical manifestations and natural history of Legius syndrome will likely occur as more affected individuals are identified.","keywords":[]}
{"symbol":"SWNTS1","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Schwannomatosis 1","alternate_names":["Schwannomatosis, somatic"],"id":"3703","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29517885\",\"@Source\":\"PubMed\"},{\"$\":\"NBK487394\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"medgen_id":"C4048809","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"162091\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93921\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000309827\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000335543\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000335548\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520026\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528460\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528885\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528886\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528909\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551659\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551660\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552305\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552306\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552308\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552477\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK487394\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"162091\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Schwannomatosis is characterized by a predisposition to develop multiple schwannomas and, less frequently, meningiomas. Individuals with schwannomatosis most commonly present between the second and fourth decade of life. The most common presenting feature is localized or diffuse pain or asymptomatic mass. Schwannomas most often affect peripheral nerves and spinal nerves. Meningiomas occur in about 5% of individuals with schwannomatosis and have only been reported in individuals with SMARCB1-related schwannomatosis. Malignancy remains a theoretic risk especially in individuals with a SMARCB1 pathogenic variant.","keywords":["Neoplasm"]}
{"disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Melanoma-pancreatic cancer syndrome","alternate_names":["FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA-PANCREATIC CARCINOMA SYNDROME"],"id":"2742","content":"{\"Citation\":[{\"@Abbrev\":\"CAPS, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3585492\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACG, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25645574\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["FAMMMPC"],"medgen_id":"C1838547","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"606719\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"404560\"}","{\"db\":\"OMIM\",\"id\":\"606719\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA-PANCREATIC CARCINOMA SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"606719\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FAMMMPC\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000325625\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501426\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502978\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520025\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530028\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552245\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569524\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Melanoma-pancreatic+cancer+syndrome/8812\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606719\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Melanoma-pancreatic cancer syndrome is an inherited cancer predisposition syndrome in which mutation carriers have an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer (summary by Harinck et al., 2012).\r\nFor background and phenotypic information on malignant melanoma and pancreatic cancer, see 155600 and 260350, respectively.","keywords":[]}
{"symbol":"LCA2","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Leber congenital amaurosis 2","alternate_names":["AMAUROSIS CONGENITA OF LEBER II","RPE65-Related Leber Congenital Amaurosis"],"id":"5384","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301475\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1298\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"30285347\",\"@Source\":\"PubMed\"},{\"$\":\"NBK531510\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31725251\",\"@Source\":\"PubMed\"},{\"$\":\"NBK549574\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":[],"medgen_id":"C1859844","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"204100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"65\"}","{\"db\":\"OMIM\",\"id\":\"204100\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMAUROSIS CONGENITA OF LEBER II\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500417\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502495\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506299\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518813\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520022\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520023\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528277\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553865\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leber+congenital+amaurosis+type+2/4136\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK549574\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"204100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"636\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"RPE65-related Leber congenital amaurosis / early-onset severe retinal dystrophy (RPE65-LCA/EOSRD) is a severe inherited retinal degeneration (IRD) with a typical presentation between birth and age five years. While central vision varies, the hallmark of this disorder is the presence of severe visual impairment with a deceptively preserved retinal structure. Vision is relatively stable in the first decade of life, but begins to decline in adolescence. Most affected individuals are legally blind (visual acuity 20/200 and/or visual fields extending \u003c20 degrees from fixation) by age 20 years. After age 20 years, visual acuity declines further and by the fourth decade all affected individuals are legally blind and many have complete loss of vision (i.e., no light perception). Milder disease phenotypes have been described in individuals with hypomorphic alleles.","keywords":[]}
{"symbol":"FXS","disease_mechanism":"loss of function","disease_mechanism_id":"273","name":"Fragile X syndrome","alternate_names":["FRAGILE X MENTAL RETARDATION SYNDROME","Fragile X syndrome, type A","MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28"],"id":"1302","content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22797890\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301558\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1384\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110344\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111012\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110946\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111547\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21540884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EMQN, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25227148\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23765048\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"medgen_id":"C0016667","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"449291\"}","{\"db\":\"Orphanet\",\"id\":\"908\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRAGILE X MENTAL RETARDATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000264966\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552393\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552933\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553203\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556541\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558826\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560955\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561923\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568236\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568277\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569426\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fragile+X+Syndrome/2906\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6464\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"613003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1384\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6464\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"FMR1 disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI). Fragile X syndrome occurs in individuals with an FMR1 full mutation or other loss-of-function variant and is nearly always characterized in affected males by developmental delay and intellectual disability along with a variety of behavioral issues. Autism spectrum disorder is present in 50%-70% of individuals with FXS. Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media. Adults may have mitral valve prolapse or aortic root dilatation. The physical and behavioral features seen in males with FXS have been reported in females heterozygous for the FMR1 full mutation, but with lower frequency and milder involvement. FXTAS occurs in individuals who have an FMR1 premutation and is characterized by late-onset, progressive cerebellar ataxia and intention tremor followed by cognitive impairment. Psychiatric disorders are common. Age of onset is typically between 60 and 65 years and is more common among males who are hemizygous for the premutation (40%) than among females who are heterozygous for the premutation (16%-20%). FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population.","keywords":[]}
{"disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","name":"Fabry disease","alternate_names":["Angiokeratoma corporis diffusum","Fabry syndrome","Fabry's disease"],"id":"1790","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_symbols":[],"medgen_id":"C0002986","type":"Disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000327665\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520062\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556725\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000503671\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522329\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000337467\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000519384\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520061\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528288\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000519366\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"}]}"],"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (α-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% α-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% α-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","keywords":[]}
{"symbol":"HCM","disease_mechanism":"Disease mechanisms vary by gene.","name":"Primary familial hypertrophic cardiomyopathy","alternate_names":["Hypertrophic cardiomyopathy"],"id":"8483","content":"{\"Citation\":[{\"@Abbrev\":\"ACC/ESC, 2003\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"14607462\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301725\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1768\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"HRS/EHRA, 2012\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"21810866\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["ASH","CMH"],"medgen_id":"C0949658","mode_of_inheritance":"Autosomal dominant and X-linked","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS192600\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"155\"}","{\"db\":\"Orphanet\",\"id\":\"99739\"}","{\"db\":\"OMIM\",\"id\":\"192600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ASH\"}","{\"db\":\"OMIM\",\"id\":\"192600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMH\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Primary+familial+hypertrophic+cardiomyopathy/9162\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"83978005\",\"ref_field\":\"name\"}"],"attribute_content":["{\"Attribute\":{\"$\":\"Various modes of inheritance\",\"@Type\":\"mode of inheritance\"},\"XRef\":{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000500683\"}}"],"keywords":[]}
{"name":"Nemaline myopathy","alternate_names":["Myopathies, Nemaline"],"id":"9537","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301465\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1288\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["NEB"],"medgen_id":"C0206157","mode_of_inheritance":"pathogenic variants in NEB gene","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS161800\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"607\"}","{\"db\":\"SNOMED CT\",\"id\":\"75072002\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"nemaline-myopathy\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Nemaline myopathy is a disorder that primarily affects skeletal muscles, which are muscles that the body uses for movement. People with nemaline myopathy have muscle weakness (myopathy) throughout the body, but it is typically most severe in the muscles of the face; neck; trunk; and other muscles close to the center of the body (proximal muscles), such as those of the upper arms and legs. This weakness can worsen over time. Affected individuals may have feeding and swallowing difficulties, foot deformities, abnormal curvature of the spine (scoliosis), and joint deformities (contractures). Most people with nemaline myopathy are able to walk, although some affected children may begin walking later than usual. As the condition progresses, some people may require wheelchair assistance. In severe cases, the muscles used for breathing are affected and life-threatening breathing difficulties can occur.Nemaline myopathy is divided into six types. In order of decreasing severity, the types are: severe congenital, Amish, intermediate congenital, typical congenital, childhood-onset, and adult-onset. The types are distinguished by the age when symptoms first appear and the severity of symptoms; however, there is overlap among the various types. The severe congenital type is the most life-threatening. Most individuals with this type do not survive past early childhood due to respiratory failure. The Amish type solely affects the Old Order Amish population of Pennsylvania and is typically fatal in early childhood. The most common type of nemaline myopathy is the typical congenital type, which is characterized by muscle weakness and feeding problems beginning in infancy. Most of these individuals do not have severe breathing problems and can walk unassisted. People with the childhood-onset type usually develop muscle weakness in adolescence. The adult-onset type is the mildest of all the various types. People with this type usually develop muscle weakness between ages 20 and 50.","keywords":[]}
